<DOC>
	<DOCNO>NCT00569712</DOCNO>
	<brief_summary>RATIONALE : Studying gene express sample blood lung fluid laboratory patient receive budesonide formoterol may help doctor learn effect budesonide formoterol gene expression biomarkers . PURPOSE : This clinical trial study gene blood lung fluid sample patient chronic obstructive pulmonary disease , without previous diagnosis lung cancer , asthma treat budesonide formoterol .</brief_summary>
	<brief_title>Studying Genes Blood Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With Without Previous Diagnosis Lung Cancer With Asthma Treated With Budesonide Formoterol</brief_title>
	<detailed_description>OBJECTIVES : - To collect integrate background information genetic , epigenetic , gene expression profile small airway cell marker inflammation bronchoalveolar lavage fluid blood patient chronic obstructive pulmonary disease ( COPD ) without prior diagnosis lung cancer patient asthma . - To examine effect budesonide/formoterol fumarate dihydrate inhalation aerosol ( Symbicort Turbuhaler ) methylation gene expression profile airway cell well inflammatory , oxidant , pathways patient . - To determine would feasible conduct large study would allow definitive analysis difference bronchial cell inflammatory protein bronchial secretion blood patient COPD without prior diagnosis lung cancer . OUTLINE : Patients receive budesonide/formoterol fumarate dihydrate inhalation aerosol ( Symbicort Turbuhaler ) twice daily 4 week absence disease progression unacceptable toxicity . Patients undergo blood sample collection bronchoscopy baseline 4 week . Blood bronchoalveolar fluid sample analyze inflammatory biomarker measurement . Bronchial brush cell sample analyze comparative genomic hybridization array , whole genome methylation array , gene expression profile . After completion study treatment , patient follow 1 week telephone interview .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Former smoker 30 packyear smoke history mild moderate degree airflow obstruction , meet follow criterion : GOLD class 1 2 chronic obstructive pulmonary disease ( COPD ) , define postbronchodilator FEV_1 &lt; 80 % predict FEV_1 FVC ratio &lt; 70 % Former smoker COPD undergone prior curative resection stage 0 I nonsmall cell lung cancer Nonsmoker mild moderate bronchial asthma already inhaled corticosteroid , meet follow criterion : Fully reversible airflow obstruction postbronchodilator FEV_1 &gt; 80 % predict No invasive cancer bronchoscopy abnormal spiral chest CT scan suspicious lung cancer PATIENT CHARACTERISTICS : ECOG performance status 01 Not pregnant nursing Fertile patient must use effective contraception Willing use study drug twice daily regularly Willing undergo bronchoscopy Not plan donate blood study participation No known suspect hypersensitivity budesonide , formoterol fumarate dihydrate , excipients study drug No know reaction xylocaine No history allergy Symbicort , Pulmicort , Oxeze Turbuhaler No significant medical condition , acute chronic respiratory failure , unstable angina , uncontrolled congestive heart failure , bleed disorder , opinion investigator , may either put patient risk due study participation preclude patient 's ability complete study No travel plan hospitalization would preclude patient 's ability complete study PRIOR CONCURRENT THERAPY : More 6 month since prior concurrent inhale corticosteroid ( e.g. , budesonide [ Pulmicort Turbuhaler ] , fluticasone [ Flovent ] , beclomethasone dipropionate [ QVAR ] , fluticasone/salmeterol [ Advair ] ) More 6 month since prior concurrent oral steroid ( e.g. , prednisone ) No concurrent montelukast No concurrent immunomodulatory immunosuppressive medication ( e.g. , antiTNF methotrexate ) No concurrent betaadrenergic blocker ( e.g. , atenolol inderal ) , orally eye drop</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>precancerous condition</keyword>
</DOC>